Anti-TSLP functional antibody

Anti-TSLP functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to TSLP/TSLP products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T85857-Ab-1/ GM-Tg-hg-T85857-Ab-2Anti-Human TSLP monoclonal antibodyHuman
GM-Tg-rg-T85857-Ab-1/ GM-Tg-rg-T85857-Ab-2Anti-Rat TSLP monoclonal antibodyRat
GM-Tg-mg-T85857-Ab-1/ GM-Tg-mg-T85857-Ab-2Anti-Mouse TSLP monoclonal antibodyMouse
GM-Tg-cynog-T85857-Ab-1/ GM-Tg-cynog-T85857-Ab-2Anti-Cynomolgus/ Rhesus macaque TSLP monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T85857-Ab-1/ GM-Tg-felg-T85857-Ab-2Anti-Feline TSLP monoclonal antibodyFeline
GM-Tg-cang-T85857-Ab-1/ GM-Tg-cang-T85857-Ab-2Anti-Canine TSLP monoclonal antibodyCanine
GM-Tg-bovg-T85857-Ab-1/ GM-Tg-bovg-T85857-Ab-2Anti-Bovine TSLP monoclonal antibodyBovine
GM-Tg-equg-T85857-Ab-1/ GM-Tg-equg-T85857-Ab-2Anti-Equine TSLP monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T85857-Ab-1/ GM-Tg-hg-T85857-Ab-2; GM-Tg-rg-T85857-Ab-1/ GM-Tg-rg-T85857-Ab-2;
GM-Tg-mg-T85857-Ab-1/ GM-Tg-mg-T85857-Ab-2; GM-Tg-cynog-T85857-Ab-1/ GM-Tg-cynog-T85857-Ab-2;
GM-Tg-felg-T85857-Ab-1/ GM-Tg-felg-T85857-Ab-2; GM-Tg-cang-T85857-Ab-1/ GM-Tg-cang-T85857-Ab-2;
GM-Tg-bovg-T85857-Ab-1/ GM-Tg-bovg-T85857-Ab-2; GM-Tg-equg-T85857-Ab-1/ GM-Tg-equg-T85857-Ab-2
Products NameAnti-TSLP monoclonal antibody
Formatmab
Target NameTSLP
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-TSLP benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-ab-567Pre-Made Tezepelumab biosimilar, Whole Mab: Anti-TSLP therapeutic antibody
    BiosimilarGMP-Bios-ab-662Pre-Made Ecleralimab biosimilar, Whole Mab: Anti-TSLP therapeutic antibody
    Target AntigenGM-Tg-g-T85857-Ag-1Recombinant multi-species TSLP protein
    ORF Viral VectorpGMLP004781human TSLP Lentivirus plasmid
    ORF Viral VectorvGMLP004781human TSLP Lentivirus particle
    ORF Viral VectorpGMLPm000289mouse Tslp Lentivirus plasmid
    ORF Viral VectorvGMLPm000289mouse Tslp Lentivirus particle


    Target information

    Target IDGM-T85857
    Target NameTSLP
    Gene ID85480,53603,688621,706194,607671,101085857,617637,100302635
    Gene Symbol and SynonymsTSLP
    Uniprot AccessionQ969D9
    Uniprot Entry NameTSLP_HUMAN
    Protein Sub-locationSecreted Protein/Potential Cytokines
    CategoryTherapeutics Target, INN Index
    DiseaseN/A
    Gene EnsemblENSG00000145777
    Target ClassificationN/A

    The target: TSLP, gene name: TSLP, also named as . This gene encodes a hemopoietic cytokine proposed to signal through a heterodimeric receptor complex composed of the thymic stromal lymphopoietin receptor and the IL-7R alpha chain. It mainly impacts myeloid cells and induces the release of T cell-attracting chemokines from monocytes and enhances the maturation of CD11c(+) dendritic cells. The protein promotes T helper type 2 (TH2) cell responses that are associated with immunity in various inflammatory diseases, including asthma, allergic inflammation and chronic obstructive pulmonary disease. The protein is therefore considered a potential therapeutic target for the treatment of such diseases. In addition, the shorter (predominant) isoform is an antimicrobial protein, displaying antibacterial and antifungal activity against B. cereus, E. coli, E. faecalis, S. mitis, S. epidermidis, and C. albicans. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, Jul 2020].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.